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PAH-DNA 以及其他肝癌风险因素对厦门市人群肝癌发病的相关性，探讨 PAH-DNA 加
合物同肝癌风险因素交互作用对肝癌的影响，为进一步开展肝癌的防治提供依据。 
方法：于 2007 年至 2009 年在厦门市多家医院开展一项以医院为基础的肝癌病
例对照研究，选择多个医院肝癌病例 345 例，可比性对照 961 例，进行行结构式问
卷调查，内容包括一般人口学特征和肝癌各种可能的暴露因素，同时采取血液标本，
应用竞争性 ELISA 法检测 DNA 加合物含量。数据用 EPIDATA3.0 输入计算机，双遍录
入校对无误后建立数据库，所有数据用 SPSS 软件分析。分别采用单因素和多因素使



































=203.57，P<0.05）。PAH-DNA 加合物还分别与 HBV 感染、不洁饮水、饮酒和吸
烟具有协同作用，超额相对危险比 RERI 值分别为 34.71，120.87，63.2，54.92。 
结论：乙型肝炎病毒感染、不洁饮水、吸烟、饮酒和 PAH-DNA 加合物都是肝癌
的危险因素，吸烟、吸烟方式、饮酒和 PAH-DNA 加合物水平对肝癌发病有剂量效应
关系， PAH-DNA 加合物水平同 HBV 感染、不洁饮水、饮酒和吸烟对肝癌有正的交互
作用。 





















HCC(hepatocellular carcinoma) is a leading disease affecting people’s health 
seriously. The number of HCC increases continuously in china and now is the second 
leading cause of death of all cancer . DNA adducts can cause DNA damage and are 
important biomakers in tumor pathogenesis research.. detection of DNA adducts level, 
their binding sites and construction can improve our knowledgement in mutagenesis and 
carcinogenesis. Studying how DNA damage affect HCC has important significancy in 
evaluating enviromental risks and cancer research.. 
Objective: extract PAH-DNA adduct from peripheral boold of population-based case 
and control, study the association of HCC and factors including PAH-DNA in peripheral 
boold, investigate how the PAH-DNA interacting with other HCC factors that affect 
tumorgenesis, to prove a foundation for prevention and control of HCC in future work.. 
Methods: we conducted the research based on case-contral study in hospitals in 
Xiamen from 2007-2009, selected 345 cases and 961 controls from several hospital in 
Xiamen, epidemiology questionary was taken and boold samples were collected. We used 
competitive ELISA to detecte the PAH-DNA adduct level. Questionaries were inputted to 
computer by EPIDATA 3.0. Data was set after check. Single factor analysis and 
non-conditional multiple logistic analysis were used to analyse relationship between 
PAH-DNA and other risks factors and HCC. All statistical analyses used SPSS 13.0. 
Results: in our study, HBsAg、contaminated drinking water、smoking and alcohol 
drinking were risk factors of HCC, their OR were81.547，1.624，7.417，13.714. Stratified 
subjects to four groups according to smoking level, OR of three groups from low to high 
were 0.65, 7.67, 19.97, compare to the nonsmoking group, there was a trend that the risk 
of HCC was increasing with smoke level（XMH2=360.6，P<0.05）. So as to alcohol 
dringking（XMH2=219.0, P<0.05）, the OR were 2.24, 4.60, 4.46, 3.71 from low to high 
drinking level compared to non-drinking group. We also found the trend that overlaying 
of smoke type could increase the risk of HCC（RERI=6.25，P<0.05）, OR of only passive 















were 0.92, 6.66，12.38, compare to nonsmoking group. 
PAH-DNA was an risk factor of HCC too, the mean level of cases group was 
(4.47±1.66 fmol/ug）, significantly higher than the mean level in controls（2.24±
1.77fmol/ug）. Stratified the subjects according to PAH-DNA level, the OR were 1.78，
5.56，7.44 from low to high group, P<0.05, compare to the lowest level group. There was 
a trend that the risk of HCC increasing with PAH-DNA adduct level（XMH2=203.57，
P<0.05）. There was an interacion between PAH-DNA and HBV affection contaminated 
drinking water、smoking、alcohol drinking, RERI values were 34.71, 120.87, 63.2, 54.92. 
Conclusions: HBsAg、contaminated drinking water、smoking、alcohol drinking and 
PAH-DNA level were risk factors of HCC. There were dose-response relationship 
between smoking、smoking type、alcohol dringking、PAH-DNA level and HCC, we also 
found evidence show interaction of those factors on HCC. 
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新发肝癌人数大约有 26 万例，其中 53%在中国，每年约有 14 万人死于肝癌，占全




































图 1.1 中国肝癌分布图。 

































































后,才能由前致癌物转变成终致癌物。细胞色素 P450 (CYP450) 酶系统为体内代谢







致细胞中癌基因 myc、ras 等或抑癌基因 p53 等表达发生改变,最终导致癌变。 
CYP4501A1 同工酶活性可受 PAHs 诱导，长期接触 PAHs 的人 CYP4501A1 酶活性
























1.3 PAH-DNA 加合物 
对 PAH-DNA 加合物的研究最早出现在职业中暴露于 PAHs 的工作者中。炼焦、
铸造和铝工业的工人经常暴露于高浓度 PAH 中。有文献报道
[24 ]
 ,早在 1876 年,就发
现接触 PAHs 的工人,尤其是焦油蒸馏间工人较常人易发生皮肤癌。动物实验已证实，




很强，经常以 B[a]P 作为 PAHs 的代表物。 
苯并芘通过 CYP450 等酶作用，在人体内的代谢终产物是二氢二醇环氧苯并芘































图 1.2 四种脱氧核苷加合物形成位点。 
Fig1.2 sites in four deoxyribonucleosides. 
 
1.4 PAH-DNA 加合物生成机制 
B[a]P 在体内首先经混合功能氧化酶(细胞色素 P450 单加氧酶)催化在结构弯
区形成 7, 8 环氧苯并芘, 然后再经环氧化物酶形成 7, 8 二氢二醇苯并芘, 此种衍
生物再经混合功能氧化酶催化, 形成二氢二醇环氧苯并芘(BPDE)。 
图 1.3 DNA 加合物生成机制 
Fig 1.3 formation of DNA adducts 
 
EH*：环氧化物酶。 
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